Company news
Spero Therapeutics, Inc. news in 2026
Spero Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 4, 2026
Spero Therapeutics to Present at Investor Conferences in November
November 2, 2026
Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
October 26, 2026
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
October 15, 2026
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 2, 2026
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
August 12, 2026
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
August 4, 2026
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
July 27, 2026
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
July 14, 2026
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
July 14, 2026
Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
July 14, 2026
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
June 17, 2026
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
May 13, 2026
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
March 25, 2026
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
March 18, 2026
Calls in 2026
Decks in 2026
- Q2 2026 Earnings Presentation
Earnings · 4 slides · Aug 12, 2026
- Investor Presentation (July 2026)
Investor deck · 28 slides · Jul 14, 2026